<DOC>
	<DOCNO>NCT03102567</DOCNO>
	<brief_summary>This study Phase I , single-center , randomize , double-blind , placebo-controlled study evaluate effect age safety , tolerability PK multiple oral dos GLPG1205 healthy male subject . The study comprise 2 part , first part investigate effect age second part investigate effect load dose .</brief_summary>
	<brief_title>This Study Evaluate Effect Aging Multiple Doses GLPG1205 Healthy Subjects</brief_title>
	<detailed_description>In Part 1 , total 24 healthy male subject match weight divide 3 age group : - Cohort A : 8 subject age 65 74 year , inclusive - Cohort B : 8 subject age ≥ 75 year ( 1:1 weight match subject Cohort A [ ±5 kg ] ) - Cohort C : 8 subject age 18-50 year , inclusive ( 1:1 weight match subject Cohort A [ ±5 kg ] ) Each cohort randomize 3:1 active ( 6 subject ) placebo ( 2 subject ) treatment respectively . Weight match subject Cohorts B C assign active treatment placebo accordingly . Cohorts A C dose 50 mg q.d . GLPG1205 14 day . In open-label Part 2 , additional cohort 8 subject age 65-74 year ( Cohort D ) include characterize PK profile load dose follow multiple dos GLPG1205 q.d . 13 day . A 250 mg load dose administer Day 1 follow 50 mg q.d . Day 2 Day 14 .</detailed_description>
	<criteria>1 . Male , age 18 year 2 . Able willing sign ICF . 3 . Able willing comply requirement study . 4 . Body Mass Index ( BMI ) 18 30 kg/m² inclusive . 5 . Weight 60 90 kg , inclusive ( Cohort A ) . 6 . Considered Investigator good health . 7 . Discontinuation medication exception occasional paracetamol 8 . Have creatinine clearance ( estimate CockroftGault equation ) &gt; 80 mL/min subject age 50 year cohort C &gt; 60 mL/min subject 65 year cohorts A , B D. 9 . A nonsmoker use nicotinecontaining product . 10 . Negative test drug screen , alcohol screen , cotinine screen . 11 . Male subject female partner childbearing potential must agree use highly effective method contraception . 1 . Known hypersensitivity GLPG1205 excipients formulation . A history significant allergic reaction drug , anaphylaxis require hospitalization . 2 . Positive serology hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) . 3 . Clinically significant illness 12 week prior study screen . 4 . Current sequelae gastrointestinal , liver kidney disease condition might interfere absorption , distribution , metabolism excretion drug . 5 . History malignancy last 5 year . 6 . Clinically significant abnormality ECG rhythm conduction 7 . Clinically significant abnormality detect physical examination vital sign . 8 . Clinically significant abnormality detect laboratory safety test 9 . Significant blood loss , include blood donation &gt; 450 mL , receive blood transfusion blood product 12 week prior study screen . 10 . Active drug alcohol abuse within 2 year prior study screen . 11 . Consumption large quantity caffeinated coffee tea ( &gt; 6 cups/day ) , equivalent . The consumption alcohol , methylxanthinecontaining beverage food ( e.g. , coffee , tea cocoa , cola chocolate ) , quinine ( e.g. , tonic water ) , grapefruit grapefruit juice , Seville oranges poppy seed within 48 h study medication administration end dose period . 12 . Concurrent recent participation investigational medicinal research study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>